Olfatifar Meysam, Rajabnia Mohsen, Sadeghi Amir, Rabbani Amirhassan, Shahrokh Shabnam, Habibi Mohammad Amin, Pezeshgi Modarres MehdiSure, Zali Mohammad Reza, Houri Hamidreza
Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran.
Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
PLoS One. 2025 May 5;20(5):e0322479. doi: 10.1371/journal.pone.0322479. eCollection 2025.
Primary sclerosing cholangitis (PSC) exhibits varying incidence and prevalence rates across different regions; however, comprehensive global studies examining its geographic distribution and future trends are scarce. This study presents an updated meta-analysis through 2024 and projects the global and regional prevalence of PSC from 2024 to 2040 using an illness-death multi-state model.
We conducted a thorough systematic search across multiple databases to identify all primary studies published until 2024 that reported on the incidence, prevalence, and mortality rates of PSC in various regions. Using the gathered data, we developed an illness-death model to forecast the future prevalence of PSC, covering the years 2024-2040.
Our meta-analysis revealed that the global pooled incidence and prevalence rates of PSC are 0.65 and 7.52 per 100,000 persons, respectively. Projections indicate that the global prevalence of PSC will rise to 22.98 cases per 100,000 (95% CI: 21.0-24.95), corresponding to an overall increase of 28.3%. Specifically, North America is forecasted to experience a 5.45% increase in PSC cases, reaching 24.76 cases per 100,000 (95% CI: 19.63-29.88), while Western Europe is anticipated to see a more pronounced rise of 28.79%, resulting in a prevalence of 21.48 cases per 100,000 (95% CI: 18.3-24.65) by 2040.
Our findings indicate a substantial rise in the number of individuals affected by PSC in recent years and estimate a significant future burden of the disease.
原发性硬化性胆管炎(PSC)在不同地区的发病率和患病率有所不同;然而,针对其地理分布和未来趋势的全面全球研究较为匮乏。本研究通过2024年的更新荟萃分析,并使用疾病 - 死亡多状态模型预测2024年至2040年全球及各地区PSC的患病率。
我们对多个数据库进行了全面的系统检索,以识别截至2024年发表的所有报告不同地区PSC发病率、患病率和死亡率的原始研究。利用收集到的数据,我们建立了一个疾病 - 死亡模型来预测2024 - 2040年PSC的未来患病率。
我们的荟萃分析显示,全球PSC的合并发病率和患病率分别为每10万人0.65例和7.52例。预测表明,全球PSC患病率将升至每10万人22.98例(95%置信区间:21.0 - 24.95),总体增长28.3%。具体而言,预计北美PSC病例将增加5.45%,达到每10万人24.76例(95%置信区间:19.63 - 29.88),而西欧预计将有更显著的28.79%的增长,到2040年患病率将达到每10万人21.48例(95%置信区间:18.3 - 24.65)。
我们的研究结果表明近年来受PSC影响的人数大幅增加,并估计了该疾病未来的重大负担。